Search research articles
Contact Us
Filters
Showing results (1-10 of 31) with videos related to
Page
of 4
Sort By:
Vaccine
|
August 7, 2017
Vaccines against Ebola virus
Navin Venkatraman, Daniel Silman, Pedro M Folegatti, et al.
Vaccine
|
April 18, 2026
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study
Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, et al.
Malaria Journal
|
March 9, 2017
A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection
Pedro M Folegatti, André M Siqueira, Wuelton M Monteiro, et al.
Human Vaccines & Immunotherapeutics
|
April 6, 2026
Immunogenicity and safety of an inactivated split-virion influenza vaccine in individuals 6 months of age and older in India
Pedro M Folegatti, Cynthia Tabar, Celine Petit, et al.
Vaccine
|
June 17, 2022
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Pedro M Folegatti, Daniel Jenkin, Susan Morris, et al.
Vaccine
|
December 15, 2024
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Kerry Conlin, Daniel Jenkin, Philip de Whalley, et al.
The Lancet. Infectious Diseases
|
May 24, 2025
Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study
Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, et al.
Vaccines
|
April 3, 2021
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Pedro M Folegatti, Amy Flaxman, Daniel Jenkin, et al.
Vaccines
|
August 28, 2021
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Chris Butler, Chris Ellis, Pedro M Folegatti, et al.
Vaccines
|
March 27, 2019
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Pedro M Folegatti, Duncan Bellamy, Amy Flaxman, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 31) with videos related to
Sort By:
Page
of 4
Vaccine
|
August 7, 2017
Vaccines against Ebola virus
Navin Venkatraman, Daniel Silman, Pedro M Folegatti, et al.
Vaccine
|
April 18, 2026
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study
Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, et al.
Malaria Journal
|
March 9, 2017
A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection
Pedro M Folegatti, André M Siqueira, Wuelton M Monteiro, et al.
Human Vaccines & Immunotherapeutics
|
April 6, 2026
Immunogenicity and safety of an inactivated split-virion influenza vaccine in individuals 6 months of age and older in India
Pedro M Folegatti, Cynthia Tabar, Celine Petit, et al.
Vaccine
|
June 17, 2022
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Pedro M Folegatti, Daniel Jenkin, Susan Morris, et al.
Vaccine
|
December 15, 2024
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial
Kerry Conlin, Daniel Jenkin, Philip de Whalley, et al.
The Lancet. Infectious Diseases
|
May 24, 2025
Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study
Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, et al.
Vaccines
|
April 3, 2021
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Pedro M Folegatti, Amy Flaxman, Daniel Jenkin, et al.
Vaccines
|
August 28, 2021
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Chris Butler, Chris Ellis, Pedro M Folegatti, et al.
Vaccines
|
March 27, 2019
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Pedro M Folegatti, Duncan Bellamy, Amy Flaxman, et al.
Page
of 4